India, April 10 -- Daxor Corporation (DXR), Thursday announced the submission of its next-generation blood volume analyzer - Daxor BVA - to the Food and Drug Administration (FDA).
The company says that its new Daxor BVA device represents a significant leap forward in diagnostic technology, offering direct quantification of intravascular blood, red blood cell, and plasma volume.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
"This submission represents a long-anticipated milestone in our commitment to patients and healthcare providers," said Michael Feldschuh, Daxor's CEO and President. "Developed under a U.S. Department of Defense contract, our next-generation analyzer promises to deliver unprecedent...